163 related articles for article (PubMed ID: 24200674)
1. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Vieira FQ; Costa-Pinheiro P; Ramalho-Carvalho J; Pereira A; Menezes FD; Antunes L; Carneiro I; Oliveira J; Henrique R; Jerónimo C
Endocr Relat Cancer; 2014 Feb; 21(1):51-61. PubMed ID: 24200674
[TBL] [Abstract][Full Text] [Related]
2. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Pires-Luís AS; Vieira-Coimbra M; Vieira FQ; Costa-Pinheiro P; Silva-Santos R; Dias PC; Antunes L; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2015; 10(11):1033-43. PubMed ID: 26488939
[TBL] [Abstract][Full Text] [Related]
3. Controllers of histone methylation-modifying enzymes in gastrointestinal cancers.
Li L; Song Q; Zhou J; Ji Q
Biomed Pharmacother; 2024 May; 174():116488. PubMed ID: 38520871
[TBL] [Abstract][Full Text] [Related]
4. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Histone Methylation in Patients with Graves' Disease.
Yan N; Mu K; An XF; Li L; Qin Q; Song RH; Yao QM; Shao XQ; Zhang JA
Int J Endocrinol; 2019; 2019():1454617. PubMed ID: 31341471
[TBL] [Abstract][Full Text] [Related]
6. Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
Santos PB; Patel H; Henrique R; Félix A
World J Clin Oncol; 2020 Feb; 11(2):43-52. PubMed ID: 32133274
[TBL] [Abstract][Full Text] [Related]
7. Decoding the Influence of Obesity on Prostate Cancer and Its Transgenerational Impact.
Santos-Pereira M; Pereira SC; Rebelo I; Spadella MA; Oliveira PF; Alves MG
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068717
[TBL] [Abstract][Full Text] [Related]
8. Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer.
Zhang L; Zhang X; Shi Y; Ni Y; Fei J; Jin Z; Li W; Wang X; Wu N
Front Oncol; 2024; 14():1376916. PubMed ID: 38525426
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
10. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
Peserico A; Germani A; Sanese P; Barbosa AJ; Di Virgilio V; Fittipaldi R; Fabini E; Bertucci C; Varchi G; Moyer MP; Caretti G; Del Rio A; Simone C
J Cell Physiol; 2015 Oct; 230(10):2447-2460. PubMed ID: 25728514
[TBL] [Abstract][Full Text] [Related]
11. SMYD proteins: key regulators in skeletal and cardiac muscle development and function.
Du SJ; Tan X; Zhang J
Anat Rec (Hoboken); 2014 Sep; 297(9):1650-62. PubMed ID: 25125178
[TBL] [Abstract][Full Text] [Related]
12. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.
Liu L; Kimball S; Liu H; Holowatyj A; Yang ZQ
Oncotarget; 2015 Feb; 6(4):2466-82. PubMed ID: 25537518
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Liu Y; Deng J; Luo X; Pan Y; Zhang L; Zhang R; Liang H
Med Oncol; 2015 Jan; 32(1):404. PubMed ID: 25471787
[TBL] [Abstract][Full Text] [Related]
15. Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
Qi L; Zhu F; Li SH; Si LB; Hu LK; Tian H
PLoS One; 2014; 9(8):e106032. PubMed ID: 25162518
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.
Costa-Pinheiro P; Patel HR; Henrique R; Jerónimo C
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1349-58. PubMed ID: 25148431
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract][Full Text] [Related]
18. Human UTY(KDM6C) is a male-specific Nϵ-methyl lysyl demethylase.
Walport LJ; Hopkinson RJ; Vollmar M; Madden SK; Gileadi C; Oppermann U; Schofield CJ; Johansson C
J Biol Chem; 2014 Jun; 289(26):18302-13. PubMed ID: 24798337
[TBL] [Abstract][Full Text] [Related]
19. Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.
Santos JI; Teixeira AL; Dias F; Gomes M; Nogueira A; Assis J; Medeiros R
Tumour Biol; 2014 Jul; 35(7):6245-53. PubMed ID: 24763824
[TBL] [Abstract][Full Text] [Related]
20. PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Khoury-Haddad H; Guttmann-Raviv N; Ipenberg I; Huggins D; Jeyasekharan AD; Ayoub N
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):E728-37. PubMed ID: 24550317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
